Prof Desmond Sheridan 1 1. 2 2 ESC mission To improve the quality of life of the European population by reducing the impact of cardiovascular disease.

Slides:



Advertisements
Similar presentations
ESC & cardiovascular prevention policy John F Martin.
Advertisements

November 2004 The Research Infrastructures in FP7 DG RTD – Directorate ‘Structuring ERA’
Indridi Benediktsson June 2007 International Collaboration in FP7 Health Research Dr. Indridi Benediktsson Directorate Health Horizontal Aspects and Coordination.
NMP-NCP meeting - Brussels, 27 Jan 2005 Towards FP 7: Preliminary principles and orientations… Nicholas Hartley European Commission DG Research DG Research.
Research & Innovation Evolution from IMI1 to IMI2: challenges ahead Elmar Nimmesgern, PhD DG Research & Innovation 1.
1 RESEARCH INFRASTRUCTURES Synergy in using FP7 and SFs for the development of Research Infrastructures Warsaw, 13 February 2006 Hervé Pero, European Commission.
Italian Presidency of the Council of the European Union July – December 2014.
Preventing chronic disease and promoting sustainable social policy Anna Coote Commissioner for Health, UKSDC December 2007.
Physical Education P.E.A.I. Mission Statement To promote a positive perception of physical activity and a balanced life style.
Women’s Heart Policy October, 2004 Gastein John O’Toole (personal capacity) Perm Rep of Irl to EU.
EU RTD + FP Cancer Treatment: A priority for patients in Europe 7 th European Health Forum Bad Gastein 7 October, 2004 Cornelius Schmaltz MD European.
Keynote address: Musculoskeletal conditions as a challenge for policy making Professor Paul Emery President of EULAR Professor of Rheumatology, University.
EU Research and Innovation Policy
European Heart Health Charter Official Launch 12 June 2007 European Parliament - Brussels "Every child born in the new millennium has the right to live.
Cardiovascular Disease: Predicting Risk and Monitoring Outcomes Monica R. Shah, MD, FACC NHLBI AIDS Coordinator Conference on Retroviruses and Opportunistic.
Council on Cardiovascular Nursing and Allied Professions CCNAP.
World Health Organization Department of Chronic Diseases and Health Promotion World Health Organization Gojka Roglic THE GLOBAL BURDEN OF DIABETES AND.
- Mobilising Actors - Universities, Researchers & the Lisbon Strategy Lesley Wilson Secretary General, European University Association (EUA) »Implementing.
The concept of Diabetes & CV risk: A lifetime risk challenge Priorities in the management of type 2 diabetes: Past, present and future Sir George Alberti,
Identifying (Strategic) Public Health Research for Policy Support Aris Sissouras University of Patras and Institute of Social Policy (EKKE) Greece European.
European Health Forum Gastein, Bad Hofgastein, Austria, September 2002 Towards the Sixth Framework Programme Parallel Forum V 26 September 2002 Public.
European Innovation Partnership on Active and Healthy Ageing 07 April 2011 Jorge Pinto Antunes Strategy and Analysis Unit DG SANCO, European Commission.
FP 6- Thematic Priority 4 Aeronautics & Space Joseph Prieur - Aeronautics DG Research- Space &Transport.
Science, research and developmentEuropean Commission Chile-EC S&T Agreement Brussels, 24 September 2002 Life Sciences, Genomics and Biotechnology for Health.
Union of Electronics, Electrical Engineering and Telecommunications (CEEC) Technical University of Sofia Third International Seminar - UPB University-
Director, DG RTD, Directorate International Cooperation
European Health Forum Gastein, Bad Hofgastein, Austria, September 2002 The Sixth Framework Programme and Policy Support Research – “Priority 8” Parallel.
What’s new in FP7 ? Main new elements compared to FP6: Annual budget from EUR 5 billion ►7 billion (mostly less in beginning years, more at the end) Duration.
European Society of Cardiology Cardiovascular diseases in women.
Why value “measurement” is critical to the future of the meetings industry development Isabel Bardinet, CEO ESC JMIC, Paris, May 2015.
ICT policies and the Lisbon Agenda Baltic IT&T 2005 Riga, 7 April 2005 Frans de Bruïne Director “Lisbon Strategy and Policies for the Information Society”
A new start for the Lisbon Strategy Executive summary Increase and improve investment in Research and Development Facilitate innovation,
A new start for the Lisbon Strategy Knowledge and innovation for growth.
FP7 - April The European Research Area in the Age of Globalisation Henri Delanghe DG RTD, C4 (Economic and Prospective Analysis Conference on Knowledge.
September 13, 2007SGH&M2B International&Training Workshop What does the European Technology Platform “Innovative Medicines initiative” offer? Vitalijs.
The Innovative Medicines Initiative A winning case for Joint Technology Initiative Status.
Clinical trials in Framework programme 7 (FP7) EU Judita Kinkorová 2. Národní konference o doporučených postupech, Olomouc 13. listopadu 2010.
FP7 /1 EUROPEAN COMMISSION - Research DG – September 2006 Building a Europe of Knowledge Towards the Seventh Framework Programme
1 Moving Towards a Knowledge-Based Economy: Progress Made Since the Lisbon EU Summit Knowledge Economy Forum III Budapest, March 23-26, 2004 Franz Kaps,
European Heart Health Charter Official Launch 12 June 2007 European Parliament - Brussels "Every child born in the new millennium has the right to live.
E u r o p e a n C o m m i s s i o nCommunity Research Global Change and Ecosystems EU environmental research : Part B Policy objectives  Lisbon strategy.
The Lisbon Strategy Liceo Scientifico A. Einstein Classe 5B A. s. 2006/2007.
Transport Programme Committee Arnoldas Milukas HoU Horizontal aspects and coordination DG RTD, Transport directorate 20 October 2010.
EHFG 7 October 2005 – Patient Safety & Research UK Presidency Workshop on Patient Safety, EHFG, Bad Hofgastein,7 September 2005 Kevin McCarthy, European.
Models/ Health Experts
Women’s Heart Health: Management challenges involved in organising and delivering effective services European Health Forum in Gastein 7 October 2004 Dr.
GENOMICS TO COMBAT RESISTANCE AGAINST ANTIBIOTICS IN COMMUNITY-ACQUIRED LRTI IN EUROPE (GRACE) H. Goossens (Coordinator), K. Loens (Manager), M. Ieven.
The Swedish EU Presidency, autumn A new Strategy for Growth and Jobs post 2010 Anna Odhner The Prime Minister’s Office.
EN Regional Policy EUROPEAN COMMISSION Communication of the Commission “The Outermost regions: an asset for Europe” Prof. Danuta Hübner Commissioner for.
T HE A LLIANCE FOR B IOMEDICAL R ESEARCH IN E UROPE ‘H IGH - LEVEL MEETING TO BRAINSTORM WITH KEY DRIVERS IN EU HEALTH RESEARCH POLICY ’ E UROPEAN P ARLIAMENT.
EU context (networks & initiatives) and expectations EU context (networks & initiatives) and expectations Michel Viaud and/or Ingrid Weiss EPIA, Brussels,
Preventable disease is causing early death and disability in Suffolk W What can we do now that will impact soon?
Strategic European Road Research Programme (SERRP IV)
NATIONAL POLICIES FOR STEPPING-UP RESEARCH, TECHNOLOGICAL DEVELOPMENT AND INNOVATION.
Commission européenne EU Employment Strategy for people with Disabilities Final Conference Conversion Strasbourg, 21 Sept Egbert Holthuis European.
Aligning Policy Agendas The case of personalised care and cure for healthy and active ageing Setting the scene for the DG Regio and Flanders Smart Specialisation.
6th Framework Programme – Research for Policy - November 2002 The Sixth Framework Programme and Policy Support Research – “Priority 8” “Priority 8” - 6th.
Richard Murrugarra – Centurion
CHALLENGES AND IMPLEMENTATION OF KNOWLEDGE BASED ECONOMY IN ESTONIA
Welcome Welcome to the {Chapter Name} PCNA Chapter Meeting!
FP6 Priority 1, Life Sciences Genomics and Biotechnology for Health
How does teamwork improve value. Dr Nils E
Promoting new measures for the protection of women workers with oncological conditions Fight against cancer and protection of workers with oncological.
The Project – EuroHeart II
Welcome!! Welcome to the {Chapter Name} PCNA Chapter Meeting!
Jean-Eric Paquet.
Research and Technological Development policy of EU
ICTPSP Call 2007 ICT for ageing well
FP6 Priority 1, Life Sciences Genomics and Biotechnology for Health
Potential effect of guidelines on ASCVD prevention in the CGPS*
Presentation transcript:

Prof Desmond Sheridan 1 1

2 2 ESC mission To improve the quality of life of the European population by reducing the impact of cardiovascular disease

Prof Desmond Sheridan 3 3 European Cardiac Society Founded in National Societies of cardiology More than 45,000 professional members Founded in National Societies of cardiology More than 45,000 professional members

Prof Desmond Sheridan 4 4 ESC Activities Education 1.ESC guidelines for prevention and treatment of CV Disease 2.Seven Scientific Journals 3.ESC Annual Congress - Stockholm Sept 3-7; 25,000 attendees Education 1.ESC guidelines for prevention and treatment of CV Disease 2.Seven Scientific Journals 3.ESC Annual Congress - Stockholm Sept 3-7; 25,000 attendees

Prof Desmond Sheridan 5 5 ESC Activities A Heart Plan for Europe 1.Supported the declaration of the Spanish Presidency in Consensus Conference in Partnership with the Irish Presidency Supported the Luxemburg Declaration in 2005 on prevention of CV Disease A Heart Plan for Europe 1.Supported the declaration of the Spanish Presidency in Consensus Conference in Partnership with the Irish Presidency Supported the Luxemburg Declaration in 2005 on prevention of CV Disease

Prof Desmond Sheridan 6 6 ESC & CVD Research Creation of a Task Force on the future of CVD Research Conference on the future of CV Research with DG RTD Share the EC’s view on the future of research Creation of a Task Force on the future of CVD Research Conference on the future of CV Research with DG RTD Share the EC’s view on the future of research

Prof Desmond Sheridan 7 7 The future of CV Research

Prof Desmond Sheridan 8 8 The future of CV Research Investment in cardiovascular research brings results CVD will remain n°1 killer globally - women, underprivileged at high risk Economic cost for the EU (direct & indirect): €300 billion/year Investment in cardiovascular research brings results CVD will remain n°1 killer globally - women, underprivileged at high risk Economic cost for the EU (direct & indirect): €300 billion/year

Prof Desmond Sheridan 9 9 The future of CV Research Challenges Clinical Research in EU has declined sharply in recent years EU has lost its dominant position as source of new treatments since 1990 Failing to attract young clinicians to science careers Challenges Clinical Research in EU has declined sharply in recent years EU has lost its dominant position as source of new treatments since 1990 Failing to attract young clinicians to science careers

Prof Desmond Sheridan 10 The future of CV Research Research priorities of the next 10 years: 1.Understanding the biological links between atherosclerosis, hypertension, diabetes and obesity 2.Prediction of atherosclerosis plaque behaviour 3.Molecular basis of failing myocardium; Differentiation of CV cells 4.Understanding change in heart rhythm Research priorities of the next 10 years: 1.Understanding the biological links between atherosclerosis, hypertension, diabetes and obesity 2.Prediction of atherosclerosis plaque behaviour 3.Molecular basis of failing myocardium; Differentiation of CV cells 4.Understanding change in heart rhythm

Prof Desmond Sheridan 11 The future of CV Research Research priorities of the next 10 years: 5. Individual tailored treatment 6.Gene & stem cell therapy 7.Mechanisms of ageing in the CV system 8.Cardiovascular vulnerability of women Research priorities of the next 10 years: 5. Individual tailored treatment 6.Gene & stem cell therapy 7.Mechanisms of ageing in the CV system 8.Cardiovascular vulnerability of women

Prof Desmond Sheridan 12 The future of CV Research Research strategy for Europe: 1.ESC strongly supports FP7 2.ESC supports a doubling of the FP7 budget  Consistent with the Lisbon strategy  to increase R&D spend as % of GDP In Europe  To reverse the decline in Europe’s R&D competitiveness Research strategy for Europe: 1.ESC strongly supports FP7 2.ESC supports a doubling of the FP7 budget  Consistent with the Lisbon strategy  to increase R&D spend as % of GDP In Europe  To reverse the decline in Europe’s R&D competitiveness

Prof Desmond Sheridan 13 The future of CV Research Research strategy for Europe: 1.ESC supports the creation of a European research Council to coordinate research in Europe 2.ESC supports the creation of a technology platform for Europe to restore R&D competitiveness Research strategy for Europe: 1.ESC supports the creation of a European research Council to coordinate research in Europe 2.ESC supports the creation of a technology platform for Europe to restore R&D competitiveness

Prof Desmond Sheridan 14 The future of CV Research Research needs to be prioritised around the needs of the people of Europe. 1.Health priorities based on causes of death and disability should direct investment. 2.Development of new biotechnologies must be directed to solving the most pressing needs to achieve their full potential. 3.“Blind” technology is not the answer. Research needs to be prioritised around the needs of the people of Europe. 1.Health priorities based on causes of death and disability should direct investment. 2.Development of new biotechnologies must be directed to solving the most pressing needs to achieve their full potential. 3.“Blind” technology is not the answer.

Prof Desmond Sheridan 15 The future of CV Research Research strategy for Europe: 1.ESC strongly supports Framework Programme 7 and the need to build a competitive knowledge based Europe. 2.New technologies need to be harnessed around well prioritised health needs in order to optimise their value. Research strategy for Europe: 1.ESC strongly supports Framework Programme 7 and the need to build a competitive knowledge based Europe. 2.New technologies need to be harnessed around well prioritised health needs in order to optimise their value.

Prof Desmond Sheridan 16